Evidence map›Paper›PMID 38115988›Full record

ArticleInternational journal of nanomedicine2023

Gadolinium Oxide Nanoparticles Reinforce the Fractionated Radiotherapy-Induced Immune Response in Tri-Negative Breast Cancer via cGAS-STING Pathway.

Boyi Yu, Xuanyi Lu, Xianglong Feng, Ting Zhao, Jiaxin Li, Yudie Lu, Fei Ye, Xiongxiong Liu, Xiaogang Zheng, Zheyu Shen and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Boyi YuBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Xuanyi LuSchool of Biomedical Engineering, Southern Medical University, Guangzhou, People's Republic of China.
Xianglong FengBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Ting ZhaoBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Jiaxin LiBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Yudie LuSchool of Biomedical Engineering, Southern Medical University, Guangzhou, People's Republic of China.
Fei YeBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Xiongxiong LiuBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Xiaogang ZhengBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Zheyu ShenSchool of Biomedical Engineering, Southern Medical University, Guangzhou, People's Republic of China.
Xiaodong JinBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Weiqiang ChenBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Qiang LiBiomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
Institute of Modern Physics · CNChinese Academy of Sciences · CNSouthern Medical University · CNUniversity of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Radiotherapy is a widely recognized first-line clinical treatment for cancer, but its efficacy may be impeded by the radioresistance of advanced tumors. It is urgent to improve the sensitivity of radioresistant tumors to radiotherapy. In this work, gadolinium oxide nanocrystals (GONs) were utilized as radiosensitizers to enhance the killing effect and reinforce the immune activation of X-ray irradiation on 4T1 breast cancer cells in vitro and in vivo. Methods: 1.0 T small animal MR imaging (MRI) system was employed to trace GONs in vivo, while 225 kVp X-ray irradiation equipment was utilized for investigating the radiosensitization of GONs in 4T1 breast cancer cells in vitro and in vivo. Western blot, quantitative real-time PCR (RT-qPCR), immunohistochemistry, immunofluorescence, clonal survival assay, flow cytometry and reactive oxygen species assay were used to explore the biological mechanism of GON sensitization. Results: GONs exhibited exceptional utility as contrast agents for both in vivo and in vitro MRI imaging. Interestingly, a single dose of 8.0 Gy X-rays together with GONs failed to confer superior therapeutic effects in tumor-bearing mice, while only 3.0 Gy × 3 fractions X-rays combined with GONs exhibited effective tumor growth inhibition. Moreover, fractionated X-ray irradiation with GONs demonstrated a superior capacity to activate the cGAS-STING pathway. Discussion: Fractionated X-ray irradiation in the presence of GONs has demonstrated the most significant activation of the anti-tumor immune response by boosting the cGAS-STING pathway.

Indexed as

NanoparticlesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorDose Fractionation, RadiationGadoliniumHumansMiceNucleotidyltransferasesGadoliniumgadolinium oxideNucleotidyltransferases4T1 breast cancer cellscGAS-STING pathwaygadolinium oxide nanoparticlesmagnetic resonance imagingradiosensitization

Identifiers

PMID38115988
PMCPMC10729773
OpenAlexW4389791310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.